Skip to content

Feed Screener MCP Methodology

⌘K

EN

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
AMF · FR
BAFIN · DE

Product

Ask the record
Help
Methodology
Signal backtests
Terms
Privacy notice
Object to processing

Language

English Español Français

Feed Screener MCP Methodology

English Español Français

Pricing Sign in

MPM BioVentures IV GmbH & Co. Beteiligungs KG — PEPLIN INC insider: 1 transactions · InsiderLens

/ / MPM BioVentures IV GmbH & Co. Beteiligungs KG

MPM BioVentures IV GmbH & Co. Beteiligungs KG

10% owner at MEMORY PHARMACEUTICALS CORP · on record since Sep 18, 2007
10% owner at PEPLIN INC · on record since Oct 30, 2008
10% owner at Pacira BioSciences, Inc. · on record since Feb 17, 2011
Former 10% Owner at Pacira BioSciences, Inc. · on record since Mar 13, 2013
10% owner at Epizyme, Inc. · on record since May 30, 2013
10% owner at Histogen Inc. · on record since Jul 24, 2013
10% owner at TriVascular Technologies, Inc. · on record since Apr 23, 2014
10% owner at CHIASMA, INC · on record since Jul 21, 2015
10% owner at Syndax Pharmaceuticals Inc · on record since Mar 9, 2016

Insider trading activity of MPM BioVentures IV GmbH & Co. Beteiligungs KG

Transactions on record: 1; since Feb 6, 2009

Open-market buys: 1; $20.7K

Open-market sells: 0

Companies traded: 1; last filing Feb 6, 2009

Figures computed from official regulatory filings — .

Companies where MPM BioVentures IV GmbH & Co. Beteiligungs KG has traded

PEPLIN INC1 tx · $20.7K · Feb 6, 2009

Track record of MPM BioVentures IV GmbH & Co. Beteiligungs KG

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of MPM BioVentures IV GmbH & Co. Beteiligungs KG

Co-insiders of MPM BioVentures IV GmbH & Co. Beteiligungs KG

EVNIN LUKECHIASMA, INC +7
GADICKE ANSBERTCHIASMA, INC +7
KAILIAN VAUGHN MCHIASMA, INC +7
MPM Asset Management Investors BV4 LLCCHIASMA, INC +7
MPM BioVentures IV GP LLCCHIASMA, INC +7

This page republishes public regulatory disclosures.

MPM BioVentures IV LLCCHIASMA, INC +7

MPM BioVentures IV QP LPCHIASMA, INC +7

Scopa James PaulCHIASMA, INC +6

Foley ToddCHIASMA, INC +5

Vander Vort JohnEpizyme, Inc. +4

BARRETT M JAMESEpizyme, Inc. +2

BARRIS PETER JEpizyme, Inc. +2

BASKETT FORESTEpizyme, Inc. +2

DOMBKOWSKI ASHLEY LMEMORY PHARMACEUTICALS CORP +2

DRANT RYAN DEpizyme, Inc. +2

Greene WilliamMEMORY PHARMACEUTICALS CORP +2

KERINS PATRICK JEpizyme, Inc. +2

KOLLURI KRISHNA KITTUEpizyme, Inc. +2

SANDELL SCOTT DEpizyme, Inc. +2

St Peter StevenMEMORY PHARMACEUTICALS CORP +2

ISALY SAMUEL DMEMORY PHARMACEUTICALS CORP +1

MPM BioVentures IV Strategic Fund, L.P.Epizyme, Inc. +1

NEA 12 GP, LLCPEPLIN INC +1

NEA Partners 12, Limited PartnershipPEPLIN INC +1

New Enterprise Associates 12, Limited PartnershipPEPLIN INC +1

ORBIMED ADVISORS LLCMEMORY PHARMACEUTICALS CORP +1

STACK DAVID MCHIASMA, INC +1

7-MED Health Ventures LPCHIASMA, INC

Aberdare GP III, L.L.C.Histogen Inc.

Aberdare Partners III LPHistogen Inc.

Aberdare Ventures III LPHistogen Inc.

Abingworth LLPCHIASMA, INC

ADVENT VENTURE PARTNERS LLPHistogen Inc.

ADVIESBEHEER GIMV LIFE SCIENCES NVMEMORY PHARMACEUTICALS CORP

Agarwal ShefaliEpizyme, Inc.

Allen Andrew REpizyme, Inc.

AMGEN INCEpizyme, Inc.

Amgen Ventures LLCEpizyme, Inc.

ARTAL GROUP S AMEMORY PHARMACEUTICALS CORP

ARTAL INTERNATIONAL SCAMEMORY PHARMACEUTICALS CORP

ARTAL SERVICES N VMEMORY PHARMACEUTICALS CORP

Astellas Venture Fund I L.P.Epizyme, Inc.

Astellas Venture Management LLCEpizyme, Inc.

BARRETT JAMES EMEMORY PHARMACEUTICALS CORP

BATE KENNETHEpizyme, Inc.

Bay City Capital Fund V Co-Investment Fund LPEpizyme, Inc.

Bay City Capital Fund V, L.P.Epizyme, Inc.

BAY CITY CAPITAL LLCEpizyme, Inc.

Bay City Capital Management V LLCEpizyme, Inc.

Bazemore Robert BEpizyme, Inc.

Concerned by this data? Exercise your right to object →

Company	Filed	Type	Qty	Price	Value · USD	Src	Details
PEPLIN INCListing unverified	Feb 6, 2009	Buy	2,648	7.80	$20.7K	SEC